Esperion Therapeutics, Inc. - 10-Q Filing

Esperion Therapeutics filed a Form 10-Q for the quarter ended March 31, 2026. The filing includes financial data and disclosures related to collaboration revenue from partners like Daiichi Sankyo Europe GmbH and Otsuka Pharmaceutical Co., Ltd., as well as details on cash equivalents, convertible debt, stock-based compensation plans, and subsequent events including a merger agreement with Essence Merger Agreement dated May 1, 2026.

SEC EDGAR · May 8, 2026, 20:12 UTC

Tickers: $ESPR

Read the full article at SEC EDGAR

More Regulatory news

First Digital Acquisition Corp Ltd. - 8-K Filing SEC EDGAR · November 12, 2026, 15:29 UTC
GROOVE BOTANICALS INC. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:24 UTC
Johnson Controls International plc - 10-K Filing SEC EDGAR · November 12, 2026, 15:24 UTC
OLD NATIONAL BANCORP /IN/ - 8-K Filing SEC EDGAR · November 12, 2026, 15:20 UTC
AMTECH SYSTEMS INC - 8-K Filing SEC EDGAR · November 12, 2026, 15:16 UTC
REGIONAL HEALTH PROPERTIES, INC - 8-K Filing SEC EDGAR · November 12, 2026, 15:09 UTC
Bitwise Avalanche ETF - 8-K Filing SEC EDGAR · November 12, 2026, 15:06 UTC
MiNK Therapeutics, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:05 UTC
Future Vision II Acquisition Corp. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:00 UTC
THUNDER MOUNTAIN GOLD INC - 10-Q Filing SEC EDGAR · November 12, 2026, 15:00 UTC